Merkoša sitáhtat
APA-čujuhus (7. p.)
Zhang, J., Larrocha, P. S., Zhang, B., Wainwright, D., Dhar, P., & Wu, J. D. (2019). Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC+ tumors respond to PD1/PD-L1 blockade therapy. BMJ Publishing Group.
Kopierejuvvon čuohpusbeavdái
Kopieren čuohpusbeavdái ii lihkostuvvan
Chicago-čujuhus (17. p.)
Zhang, Jinyu, Pablo Saenz-lopez Larrocha, Bin Zhang, Derek Wainwright, Payal Dhar, juo Jennifer D. Wu. Antibody Targeting Tumor-derived Soluble NKG2D Ligand SMIC Provides Dual Co-stimulation of CD8 T Cells and Enables SMIC+ Tumors Respond to PD1/PD-L1 Blockade Therapy. BMJ Publishing Group, 2019.
Kopierejuvvon čuohpusbeavdái
Kopieren čuohpusbeavdái ii lihkostuvvan
MLA-čujuhus (9. p.)
Zhang, Jinyu, et al. Antibody Targeting Tumor-derived Soluble NKG2D Ligand SMIC Provides Dual Co-stimulation of CD8 T Cells and Enables SMIC+ Tumors Respond to PD1/PD-L1 Blockade Therapy. BMJ Publishing Group, 2019.
Kopierejuvvon čuohpusbeavdái
Kopieren čuohpusbeavdái ii lihkostuvvan
Muitte dárkkistit čujuhemiid riektatvuođa, ovdal go geavahat daid iežat deavsttas.